EQL Pharma
55.00 SEK
-1.43 %
Less than 1K followers
EQL
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-1.43 %
-5.17 %
-4.84 %
-4.84 %
-17.04 %
-23.40 %
+47.06 %
+58.50 %
+923.30 %
EQL Pharma operates in the pharmaceutical industry and focuses on the development, manufacturing and distribution of generic medicines. The company's products are aimed at healthcare institutions and patients who need cost-effective treatment options. The business is global with a primary presence in Europe, North America and Asia. EQL Pharma was founded in 2006 and is headquartered in Lund, Sweden.
Read moreMarket cap
1.62B SEK
Turnover
52.84K SEK
Revenue
373.52M
EBIT %
18.04 %
P/E
37.16
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
8.5
2026
Annual report '26
20.8
2026
General meeting '26
All
Press releases
3rd party
ShowingAll content types
EQL Pharma: Mellozzan® (melatonin) has been approved in Italy
EQL Pharma: Nomination committee for the 2026 Annual General Meeting
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools